BRPI0715936A2 - a composiÇço dos antibiàticos que compreende antibiàticos beta-lactamicos e agentes quelantes iânicos. - Google Patents

a composiÇço dos antibiàticos que compreende antibiàticos beta-lactamicos e agentes quelantes iânicos.

Info

Publication number
BRPI0715936A2
BRPI0715936A2 BRPI0715936-6A2A BRPI0715936A BRPI0715936A2 BR PI0715936 A2 BRPI0715936 A2 BR PI0715936A2 BR PI0715936 A BRPI0715936 A BR PI0715936A BR PI0715936 A2 BRPI0715936 A2 BR PI0715936A2
Authority
BR
Brazil
Prior art keywords
beta
antibiotics
chelating agents
lactam antibiotics
ionic
Prior art date
Application number
BRPI0715936-6A2A
Other languages
English (en)
Inventor
Hesheng Zhang
Original Assignee
Tianjin Hemay Bio Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Bio Tech Co Ltd filed Critical Tianjin Hemay Bio Tech Co Ltd
Publication of BRPI0715936A2 publication Critical patent/BRPI0715936A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A COMPOSIÇçO DOS ANTIBIàTICOS QUE COMPREENDE ANTIBIàTICOS BETALACTAMICOS E AGENTES QUELANTES IâNICOS. Os antibióticos compostos compreendendo pelo menos um dos antibióticos beta-lactâmicos e pelo menos um dos agentes quelatantes iônicos utilizado para inibir a formação de partículas, ainda que inclua pelo menos um dos inibidores da beta-lactamase ou amortecedores, ou pelo menos um dos inibidores da beta-lactamase e amortecedores simultaneamente. A composição pode ser formulada com, pelo menos um dos antibióticos aminoglicosídicos, em solução para o controle da infecção microbiana em um recipiente.
BRPI0715936-6A2A 2006-08-25 2007-08-14 a composiÇço dos antibiàticos que compreende antibiàticos beta-lactamicos e agentes quelantes iânicos. BRPI0715936A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006100154378A CN101129381B (zh) 2006-08-25 2006-08-25 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
PCT/CN2007/002438 WO2008025226A1 (en) 2006-08-25 2007-08-14 The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents

Publications (1)

Publication Number Publication Date
BRPI0715936A2 true BRPI0715936A2 (pt) 2013-09-17

Family

ID=39126891

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715936-6A2A BRPI0715936A2 (pt) 2006-08-25 2007-08-14 a composiÇço dos antibiàticos que compreende antibiàticos beta-lactamicos e agentes quelantes iânicos.

Country Status (11)

Country Link
US (1) US8426373B2 (pt)
EP (1) EP2062581B1 (pt)
JP (1) JP5330241B2 (pt)
KR (1) KR20090042993A (pt)
CN (1) CN101129381B (pt)
AU (1) AU2007291765B2 (pt)
BR (1) BRPI0715936A2 (pt)
CA (1) CA2661754A1 (pt)
DK (1) DK2062581T3 (pt)
RU (1) RU2009102849A (pt)
WO (1) WO2008025226A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
KR20110058887A (ko) * 2008-09-18 2011-06-01 마누 차우드하리 신규한 단일 유닛 카바페넴 아미노글라이코사이드 제형
CN101590061B (zh) * 2009-04-14 2010-09-29 深圳立健药业有限公司 一种头孢替坦二钠的药物组合物
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
TR200909787A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
CN101940572A (zh) * 2010-01-21 2011-01-12 深圳市新泰医药有限公司 一种头孢孟多酯钠和他唑巴坦钠的组合物及其配比
CN101940573B (zh) * 2010-01-21 2013-03-20 深圳市新泰医药有限公司 一种头孢孟多酯钠和舒巴坦钠的组合物及其配比
TR201000688A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
EP2568959A2 (en) * 2010-05-14 2013-03-20 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
CN101904817B (zh) * 2010-07-27 2011-09-28 海南永田药物研究院有限公司 一种头孢磺啶钠脂质体注射剂
CN102652751A (zh) * 2011-03-04 2012-09-05 珠海联邦制药股份有限公司 一种含有头孢噻肟的药物组合物及其制剂和制备方法
WO2012131690A1 (en) * 2011-03-30 2012-10-04 Aggarwal Kumar Vijay Drug delivery form as a bilayer tablet
CN102210676A (zh) * 2011-05-04 2011-10-12 湖南湘药制药有限公司 含磺苄西林钠与克拉维酸类化合物的抗菌组合药物
RU2455989C1 (ru) * 2011-05-11 2012-07-20 Лимонов Виктор Львович Фармацевтическая композиция для лечения инфекционных болезней, вызванных множественно-устойчивыми бактериями
CN102198105B (zh) * 2011-05-19 2012-12-05 石药集团中诺药业（石家庄）有限公司 萘夫西林钠注射剂及其制备方法
MX352760B (es) * 2011-09-09 2017-12-07 Merck Sharp & Dohme Corp Star Metodos para tratar infecciones intrapulmonares.
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ４’−デスフェリチオシン類似体の使用
CN103193838B (zh) * 2012-01-06 2016-08-24 上海医药工业研究院 依替米星硫酸盐的假多晶型、其制备方法及其应用
CN103193837B (zh) * 2012-01-06 2015-08-26 上海医药工业研究院 制备硫酸依替米星的方法
GB201208080D0 (en) * 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN103012430B (zh) * 2013-01-16 2014-08-06 湖北济生医药有限公司 美洛西林钠化合物及其药物组合物
BR112015021755A2 (pt) * 2013-03-07 2017-07-18 Kane Biotech Inc composições antimicrobianas e antibiofilmes e métodos de aplicação das mesmas
DK2893929T3 (da) 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP2986119B1 (en) 2013-04-16 2019-08-14 University Of Cincinnati Antimicrobial compositions of aminoglycosidic antibiotics and zinc ion chelators
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CA2930966A1 (en) 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
CN104382899B (zh) * 2014-11-20 2021-02-12 重庆福安药业(集团)股份有限公司 一种美洛西林钠舒巴坦钠的复方药物组合物
WO2016154547A1 (en) * 2015-03-26 2016-09-29 University Of Florida Research Foundation, Incorporated Use of metal chelators in managing infectious diseases
CN104739781A (zh) * 2015-04-03 2015-07-01 海南通用康力制药有限公司 一种注射用美洛西林钠无菌粉针剂的制备方法
EP3288557A4 (en) 2015-04-27 2018-11-07 University of Florida Research Foundation, Inc. Metabolically programmed metal chelators and uses thereof
CN106176625B (zh) * 2015-04-29 2019-05-31 重庆福安药业(集团)股份有限公司 注射用拉氧头孢钠的药物组合物
CN105085543A (zh) * 2015-09-10 2015-11-25 青岛蓝盛洋医药生物科技有限责任公司 一种抗菌药物舒巴坦钠组合物
CN106074543B (zh) * 2016-07-13 2019-06-21 福建傲农生物科技集团股份有限公司 一种含阿莫西林的水溶性增效组合物及其应用
AU2017295866A1 (en) 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
CN106420760A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯组合物
CN106389358A (zh) * 2016-11-09 2017-02-15 重庆福安药业集团庆余堂制药有限公司 减少过敏反应的注射用头孢哌酮钠舒巴坦钠的药物组合物
CN106749332B (zh) * 2016-12-02 2018-11-09 河北联合制药有限公司 氨苄西林钠晶体的生产工艺
CN108802241A (zh) * 2017-05-05 2018-11-13 江苏灵豹药业股份有限公司 一种注射用头孢噻肟钠他唑巴坦钠中有关物质的液相色谱-串联质谱定性分析方法
CN110314163A (zh) * 2018-03-30 2019-10-11 杭州森泽医药科技有限公司 一种拉氧头孢钠药物组合物及应用
CN109432101A (zh) * 2018-12-03 2019-03-08 辽宁海思科制药有限公司 头孢哌酮钠他唑巴坦钠药物组合物及其制备方法
US20220096411A1 (en) * 2019-01-24 2022-03-31 The Broad Institute, Inc. Combining metabolic stimulation and amino acids to sensitize tolerant bacteria to antibiotics
CN110237032A (zh) * 2019-07-24 2019-09-17 广州市白云健药品有限公司 一种萘夫西林钠注射剂及其制备方法
CN114159432B (zh) * 2020-09-11 2024-01-09 成都倍特药业股份有限公司 一种替卡西林钠克拉维酸钾药物组合物及其制备方法
USD1043763S1 (en) * 2022-10-31 2024-09-24 Nye Manufacturing Ltd. Stump harvester
CN117582404A (zh) * 2023-12-07 2024-02-23 上海欣峰制药有限公司 一种注射用头孢地嗪钠制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141822A (en) * 1962-03-05 1964-07-21 Olin Mathieson Stable compositions of alkali metal salts of synthetic penicillins and polyacetic acids
US5998381A (en) * 1996-12-06 1999-12-07 Ophidian Pharmaceuticals, Inc. Compounds that bind bacterial pili
DE69829605T2 (de) * 1997-05-02 2006-02-09 Seikagaku Corp. Chondroitinase enthaltende Zusammensetzungen
CN1198611C (zh) * 1999-09-17 2005-04-27 第一三得利制药株式会社 药物抗菌剂组合物
DK1468697T3 (da) * 2003-04-14 2008-04-14 Wyeth Corp Sammensætninger indeholdende piperacillin og tazobactam, der er anvendelige til injektion
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
ATE476981T1 (de) * 2004-12-02 2010-08-15 Venus Remedies Ltd Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
US20080227732A1 (en) * 2005-05-13 2008-09-18 Venus Remedies Limited Treatment and Control of Severe Infections Including Cystic Fibrosis

Also Published As

Publication number Publication date
JP5330241B2 (ja) 2013-10-30
KR20090042993A (ko) 2009-05-04
AU2007291765B2 (en) 2013-03-21
EP2062581A4 (en) 2009-11-25
RU2009102849A (ru) 2010-09-27
US8426373B2 (en) 2013-04-23
JP2010501492A (ja) 2010-01-21
EP2062581A1 (en) 2009-05-27
DK2062581T3 (da) 2012-10-08
CA2661754A1 (en) 2008-03-06
CN101129381B (zh) 2012-02-01
WO2008025226A1 (en) 2008-03-06
US20090155387A1 (en) 2009-06-18
AU2007291765A1 (en) 2008-03-06
EP2062581B1 (en) 2012-06-27
CN101129381A (zh) 2008-02-27

Similar Documents

Publication Publication Date Title
BRPI0715936A2 (pt) a composiÇço dos antibiàticos que compreende antibiàticos beta-lactamicos e agentes quelantes iânicos.
BRPI0715935A2 (pt) a composiÇço antibiàtica contendo os antibiàticos beta-lactÂmicos e amortecedores.
MX338505B (es) Combinaciones utiles de antibioticos de monobactama con inhibidores de beta-lactamasa.
NI201000115A (es) Inhibidores de beta-lactamasa.
CL2011000783A1 (es) Combinacion sinergica de un compuesto heterociclico nitrogenado de formula i antibacteriano con otro compuesto antibacteriano; medicamento; composicion farmaceutica; util para tratar infecciones bacterianas.
NO20042271L (no) Formuleringer som inneholder en cefalosporinforbindelse og deres anvendelse for behandling av bakterielle infeksjoner i katter og hunder
EA201000774A1 (ru) Ингибиторы бета-лактамазы
WO2007097940A3 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
BR112017027719A2 (pt) composto, zwitterion, composição farmacêutica, métodos para inibir betalactamase em um indivíduo e para tratamento de uma infecção bacteriana, e, uso de um composto
AR059444A1 (es) Composiciones ramnolipidicas y metodos de uso relacionados
TW200734344A (en) Antibacterial agents
Paukner et al. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum β-lactamase inhibitor
PE20240149A1 (es) Compuestos de lactivicina, su preparacion y uso como agentes antibacterianos
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
Castagnola et al. Differences in the proportions of fluoroquinolone‐resistant Gram‐negative bacteria isolated from bacteraemic children with cancer in two Italian centres
BRPI0514723B8 (pt) composições contendo componentes de agonista alfa-2-adrenérgico
TW200716104A (en) Tricyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
BRPI0515376A (pt) método para prevenir ou tratar diarréia em um mamìfero, composição útil na prevenção ou no tratamento de diarréia em um mamìfero, kit adequado para administrar um exopolissacarìdeo microbiano a um mamìfero, e, meio para comunicar informação
Lin et al. Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections
BRPI0613999B8 (pt) uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto
MX2010014248A (es) Nuevos antibioticos de trinem e inhibidores de beta-lactamasas.
BRPI0708098B8 (pt) derivados de 4-benzoilaminofenil)-6,7-dimetóxi-2-metilaminoquinazolina, composição farmacêutica e agente antiprurítico
EA202191461A1 (ru) Комбинированные композиции, содержащие ингибитор -лактамазы, и пути их применения
WO2008140577A3 (en) Cd44 pathway antagonists for treatment of adenoviral infection
CY1113234T1 (el) Τοπικη ενδορρινικη συνθεση που μπορει να χρησιμοποιηθει στην περιπτωσh ρινικης αποφραξhς

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.